

1. ☒ Specification 40 pages (including specification, claims, abstract) / 26 claims (6 independent), after entry of the Preliminary Amendment.
2. ☒ Declaration/Power of Attorney:
  - ☒ Copy from Prior Application (for continuation or divisional application)
  - ☐ Newly Executed Declaration (for CIP application)
  - ☐ Deferred under 37 C.F.R. § 1.53(f)
  - ☐ Deletion of Inventor(s) - Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b)
  - ☒ Incorporation by Reference - The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein
3. ☐      Distinct sheets of ☐ Formal and ☐ Informal Drawings

# UNITED STATES CONTINUING UTILITY PATENT APPLICATION

under 37 C.F.R. § 1.53(b)

Page 2

Atty. Docket No. 04163-00124

4. ☒ Preliminary Amendment is enclosed.  
☒ Amend the specification by inserting before the first line of the first paragraph the following sentence:  
-- This application is a continuation of U.S. Patent No. Application Serial No. 09/196,403, filed November 19, 1998; which claims priority from U.S. Provisional Patent Application No. 60/066,187, filed November 19, 1997. --

5. ☐ Information Disclosure Statement  
☐ Form 1449  
☐ A copy of each cited prior art reference

6. ☐ Assignment  
☐ Assignment with Cover Sheet attached  
☒ Assignment filed in prior application. Application assigned to: OraCeutical LLC, of Monterey, Massachusetts.

7. ☐ Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s) (provisional and foreign applications):

Country	Application Number	Date of Filing (day, month, year)
US	60/066,187	19 NOV 1997

8. ☒ Priority is hereby claimed under 35 U.S.C. § 120 based upon the following applications:

Country	Application Number	Date of Filing (day, month, year)
US	09/196,403	19 NOV 1998

9. ☐ Priority document(s)

10. ☒ Small Entity Statement  
☒ Small Entity Statement was filed in prior application, Small Entity Status is still proper and desired.  
☐ Small Entity status is being claimed hereby.  
☐ is no longer claimed.

11. ☐ Microfiche Computer Program (Appendix)

12. ☐ Nucleotide and/or Amino Acid Sequence Submission  
☐ Computer Readable Copy  
☐ Paper Copy (identical to computer copy)  
☐ Statement verifying identity of above copies

**UNITED STATES CONTINUING UTILITY PATENT APPLICATION**  
under 37 C.F.R. § 1.53(b)

Page 3

Atty. Docket No. 04163-00124

13. Calculation of Fees:

FEES FOR	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			\$710.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	6	18.00	\$108.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	3	80.00	\$240.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	0	270.00	\$0.00
Subtotal - Filing Fee Due			\$1,058.00
	MULTIPLY BY		
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0.50		\$529.00
<b>TOTAL FILING FEE DUE</b>			<b>\$529.00</b>
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$0.00
<b>GRAND TOTAL DUE</b>			<b>\$529.00</b>

14. PAYMENT is:

- ☒ The Commissioner is authorized to debit the instant filing fee, in the amount of \$529.00, and any other fees during the pendency of this application under 37 C.F.R. §§ 1.16, 1.17 and 1.18, to Deposit Account No. 19-0733. A duplicate copy of this letter is enclosed.
- ☐ not included, but deferred under 37 C.F.R. § 1.53(f)

15. All correspondence for the attached application should be directed to:

John P. Iwanicki  
BANNER & WITCOFF, LTD. Customer No. 22910  
28 State Street, 28th Floor  
Boston, MA 02109  
Telephone: (617) 227-7111  
Facsimile: (617) 227-4399

16. Other: \_\_\_\_\_

Date: April 24, 2001

By:   
John P. Iwanicki, Reg. No. 34,628

JPI/lh  
Enclosures